Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermalex Eczema is a non-steroidal topical cream developed for the treatment of mild to moderate atopic dermatitis (eczema). Classified as a medical device or cosmetic-type formulation rather than a traditional pharmaceutical drug, it is designed to restore and fortify the skin barrier. Its primary active components include a skin-identical ceramide complex and a proprietary MagnoLite complex (modified alumino-silicates and alkaline earth minerals). These ingredients work synergistically to replenish missing natural ceramides and activate the skin's own repair mechanisms, creating a protective layer that prevents moisture loss and blocks environmental triggers. The product is free from corticosteroids, calcineurin inhibitors, artificial colorings, and parabens, making it suitable for long-term use in both adults and children aged 6 years and over. It was studied in randomized trials in collaboration with the Amsterdam Medical Center (AMC) and is marketed as a standalone or adjunct therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermalex Eczema.